Combination of antihypertensive therapy in the elderly, multicenter investigation (CAMUI) trial rationale and design

International Heart Journal

Volumn 53, Issue 4, 2012, Pages 244-248

  Sato, Nobuyuki ^a   Saijo, Yasuaki ^a   Hasebe, Naoyuki ^a  

^a ASAHIKAWA MEDICAL COLLEGE   (Japan)

Author keywords

Antihypertensive agents; Cognitive function; Combination therapy

Indexed keywords

ALBUMIN; AMLODIPINE; CANDESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; LOSARTAN; OLMESARTAN; TELMISARTAN; VALSARTAN;

AGED; ALBUMINURIA; ARTICLE; BLOOD PRESSURE REGULATION; COGNITION; COMBINATION CHEMOTHERAPY; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELDERLY CARE; FEMALE; FOLLOW UP; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; ANGIOTENSIN RECEPTOR ANTAGONISTS; CALCIUM CHANNEL BLOCKERS; COGNITION; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYPERTENSION; MALE; RESEARCH DESIGN;

EID: 84864941684     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.53.244     Document Type: Article

References (29)

1. Mori H, Ukai H, Yamamoto H, et al. Current status of antihypertensive prescription and associated blood pressure control in Japan. Hypertens Res 2006; 29: 143-51.
2. Ogihara T, Kikuchi K, Matsuoka H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
3. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25: 1105-87.
4. Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Am Soc Hypertens 2010; 4: 42-50.
5. Overlack A, Ruppert M, Kolloch R, Kraft K, Stumpe KO. Age is a major determinant of the divergent blood pressure responses to varying salt intake in essential hypertension. Am J Hypertens 1995; 8: 829-36.
6. Saruta T, Ogihara T, Matsuoka H, et al. Antihypertensive efficacy and safety of fixed-dose combination therapy with losartan plus hydrochlorothiazide in Japanese patients with essential hypertension. Hypertens Res 2007; 30: 729-39.
7. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-9.
8. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002; 359: 995-1003.
9. Shimosawa T, Gohchi K, Yatomi Y, Fujita T. Effectiveness of addon low-dose diuretics in combination therapy for hypertension: losartan/hydrochlorothiazide vs. candesartan/amlodipine. Hypertens Res 2007; 30: 831-7.
10. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004; 65: 2309-20.
11. Khosla N, Bakris G. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol 2006; 1: 229-35. (Review)
12. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-52.
13. Jamerson K, Weber MA, Bakris GL, et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-28.
14. Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomized controlled trial. Lancet 2010; 375: 1173-81.
15. Bakris GL, Toto RD, McCullough PA, et al. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. Kidney Int 2008; 73: 1303-9.
16. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomized controlled trial. Lancet 2005; 365: 939-46.
17. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitorassociated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 2000; 160: 685-93.
18. Mann JF, Schmieder RE, Dyal L, et al. Effect of telmisartan on renal outcomes: a randomized trial. Ann Intern Med 2009; 151: 1-10.
19. So WY, Kong AP, Ma RC, et al. Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-52.
20. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomized double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-51.
21. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo controlled trial. Lancet Neurol 2008; 7: 683-9.
22. Freitag MH, Peila R, Masaki K, et al. Midlife pulse pressure and incidence of dementia: the Honolulu-Asia Aging Study. Stroke 2006; 37: 33-7.
23. Savaskan E, Hock C, Olivieri G, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer's dementia. Neurobiol Aging 2001; 22: 541-6.
24. Li NC, Lee A, Whitmer RA, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010; 340: b5465.
25. Schrader J, Lüders S, Diener HC, et al. Effects of long-term antihypertensive therapy with losartan on blood pressure and cognitive function in patients with essential hypertension and other cerebrovascular risk factors (AWARE observational study). Med Klin (Munich) 2008; 103: 491-9. (German)
26. Fogari R, Mugellini A, Zoppi A, et al. Influence of losartan and atenolol on memory function in very elderly hypertensive patients. J Hum Hypertens 2003; 17: 781-5.
27. Ohrui T, Tomita N, Sato-Nakagawa T, et al. Effects of brain-penetrating ACE inhibitors on Alzheimer disease progression. Neurology 2004; 63: 1324-5.
28. Zhu D, Shi J, Zhang Y, et al. Central angiotensin II stimulation promotes β amyloid production in Sprague Dawley rats. PLoS One 2011; 6: e16037.
29. Danielyan L, Klein R, Hanson LR, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res 2010; 13: 195-201.